Business Description
Ascentage Pharma Group International
ISIN : KYG0519B1023
Compare
Compare
Traded in other countries / regions
06855.Hong Kong36X.GermanyASPHF.USA IPO Date
2019-12-23Description
Ascentage Pharma Group International is a clinical-stage biotechnology company engaged in the development and sales of novel small-scale therapies for cancers, hepatitis B virus, or HBV, and certain age-related diseases. It focuses on developing therapies that inhibit protein-protein interactions to restore apoptosis or programmed cell death. The company's geographical segments include the United States and Mainland China.
Financial Strength
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.65 | |||||
| Equity-to-Asset | 0.25 | |||||
| Debt-to-Equity | 2.22 | |||||
| Debt-to-EBITDA | -6.18 | |||||
| Piotroski F-Score | 2/9 | |||||
| Altman Z-Score | -0.84 | |||||
| Beneish M-Score | -1.6 | |||||
| WACC vs ROIC | ||||||
Growth Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 133 | |||||
| 3-Year EBITDA Growth Rate | 6.5 | |||||
| 3-Year EPS without NRI Growth Rate | 1 | |||||
| 3-Year FCF Growth Rate | 13.8 | |||||
| 3-Year Book Growth Rate | -62.8 | |||||
| Future 3-5Y Total Revenue Growth Rate | 78.47 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 56.29 | |||||
| 9-Day RSI | 53.54 | |||||
| 14-Day RSI | 53.27 | |||||
| 6-1 Month Momentum % | 159.9 | |||||
| 12-1 Month Momentum % | 82.29 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.84 | |||||
| Quick Ratio | 1.83 | |||||
| Cash Ratio | 1.03 | |||||
| Days Inventory | 141.91 | |||||
| Days Sales Outstanding | 131.13 | |||||
| Days Payable | 902.93 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -8.7 | |||||
| Shareholder Yield % | -4.17 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 96.94 | |||||
| Operating Margin % | -36.92 | |||||
| Net Margin % | -40.77 | |||||
| FCF Margin % | -83.22 | |||||
| ROE % | -77.5 | |||||
| ROA % | -12.84 | |||||
| ROIC % | -18.02 | |||||
| ROC (Joel Greenblatt) % | -30.43 | |||||
| ROCE % | -15.18 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 12.73 | |||||
| PB Ratio | 16 | |||||
| Price-to-Tangible-Book | 19.26 | |||||
| EV-to-EBIT | -43.66 | |||||
| EV-to-EBITDA | -47.71 | |||||
| EV-to-Revenue | 14.51 | |||||
| EV-to-FCF | -17.26 | |||||
| Earnings Yield (Greenblatt) % | -2.3 | |||||
| FCF Yield % | -6.12 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Ascentage Pharma Group International Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 115.667 | ||
| EPS (TTM) (€) | -0.162 | ||
| Beta | 0.3 | ||
| Volatility % | 66 | ||
| 14-Day RSI | 53.27 | ||
| 14-Day ATR (€) | 0.148686 | ||
| 20-Day SMA (€) | 5.1405 | ||
| 12-1 Month Momentum % | 82.29 | ||
| 52-Week Range (€) | 1.83 - 5.65 | ||
| Shares Outstanding (Mil) | 315.2 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Ascentage Pharma Group International Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Ascentage Pharma Group International Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Ascentage Pharma Group International Frequently Asked Questions
What is Ascentage Pharma Group International(STU:36X)'s stock price today?
The current price of STU:36X is €5.20. The 52 week high of STU:36X is €5.65 and 52 week low is €1.83.
When is next earnings date of Ascentage Pharma Group International(STU:36X)?
The next earnings date of Ascentage Pharma Group International(STU:36X) is 2025-02-22 Est..
Does Ascentage Pharma Group International(STU:36X) pay dividends? If so, how much?
Ascentage Pharma Group International(STU:36X) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers